Pfizer pays $135M to ease Exubera pain

Exubera fallout alert: Pfizer has reached a deal with its partner on the drug, Nektar Therapeutics. The drug giant will pay Nektar $135 million for its trouble. And if Nektar finds a new partner to help it develop the inhaled insulin product, Pfizer will hand over all its rights to the new venture.

Meanwhile, Consort Medical, which made plastic applicators for the product, is shutting a plant and laying off 165. The manufacturing facility, located in Milton Keynes, England, will be sold.

You'll recall that Pfizer took a $2.8 billion charge against earnings in the third quarter to pay for pulling the plug on the once-so-promising Exubera.

- check out Pfizer's release
- see this report on Nektar from CNN Money
- read about Consort's consolidation in Plastics & Rubber Weekly

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.